Clinical Trials

Phase 2 Active not recruiting

Breast Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT01803282 2020-06-02

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

BreastGastrointestinalThoracic

236 enrolled 21 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00003867 2018-09-10

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

30 enrolled

BreastGastrointestinal

Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT02030678 2018-09-05

A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer

Phase 2 Unknown

124 enrolled

BreastGastrointestinalSarcomaThoracic

Breast Neoplasms, Recurrence

NCT02331251 2018-07-02

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Phase 1/2 Terminated

81 enrolled

Breast Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT03562390 2018-06-19

Irinotecan for Advanced and Metastatic Breast Cancer

Phase 2 Unknown

124 enrolled

Breast Neoplasms

NCT00617539 2018-04-20

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

30 enrolled 10 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00303992 2018-01-17

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

9 enrolled

Breast Neoplasms

NCT00004095 2017-04-18

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryThoracic

38 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00079118 2016-12-13

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

70 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00275041 2016-12-13

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

21 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00003351 2016-07-14

Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer

104 enrolled

Breast Neoplasms

NCT00693719 2015-11-20

Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer

31 enrolled 8 charts

Breast Neoplasms

NCT01939483 2014-10-08

A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases

Phase NA Withdrawn

Breast Neoplasms, Breast Neoplasms, Male

NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

41 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01501669 2012-07-18

PROCEED

Phase 3 Unknown

222 enrolled

Breast Neoplasms

NCT00004182 2012-06-06

Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer

Breast Neoplasms

NCT00083148 2011-03-09

Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

12 enrolled

Breast Neoplasms

NCT00072852 2008-10-16

Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

134 enrolled